Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A. by KATIE THOMAS

By KATIE THOMAS

Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the F.D.A. while seeking approval for its $2.1 million gene therapy.

Published: August 6, 2019 at 08:00PM

from NYT Health https://ift.tt/2YPZ7N5
via IFTTT

from WordPress https://ift.tt/2YPu4Ri
via IFTTT